Novartis announces a five-year commitment to the fight against malaria. They have also released new African research on progress and remaining challenges toward the 2030 malaria elimination targets.
In order to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030, Novartis have comitted to investing over 100 million USD to advance research and development of next-generation treatments. In order to enable patients in malaria-endemic countries to afford these new treatments once they become available, the company will implement an equitable pricing strategy based on socio-economic conditions of different population segments.
The R&D investment is meant to advance the Novartis malaria pipeline through 2023 and to complete a comprehensive global clinical trial program for our novel antimalarial drug candidates KAF156 and KAE609. The investment also includes new uses of technology to identify areas where the malaria burden is greatest.
Vas Narasimhan, CEO of Novartis said, “Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait.”